Background Loiasis is a vector-borne disease in Central and West Africa. While there is still
uncertainty to what extent loiasis is responsible for population morbidity, individuals having …

Background Loiasis is a vector-borne disease in Central and West Africa. While there is still
uncertainty to what extent loiasis is responsible for population morbidity, individuals having …

Background Loiasis is a highly prevalent helminth infection found in distinct regions of sub-
Saharan Africa. The disease has been considered to be of minor clinical significance, but …

Several cases of severe adverse reactions to ivermectin treatment have been reported from
Cameroon in individuals with a high intensity of Loa loa infection. Concerns about possible …

Background Loiasis is a major obstacle to ivermectin treatment for onchocerciasis control
and lymphatic filariasis elimination in central Africa. In communities with a high level of …

Background More than 20 million people are infected with L. loa, and around 40 million live
in high or intermediate-risk areas in West-and Central Africa. Although loiasis is associated …

Background Individuals with high microfilarial loads of Loa loa are at increased risk of
neurologic serious adverse (SAE) events following ivermectin treatment against …

Abstract Community-Directed Treatment with Ivermectin (CDTI) is the strategy of choice to
fight onchocerciasis in Africa. In areas where loiasis is endemic, onchocerciasis control …

Background Loiasis is currently receiving attention as a disease of public health importance
because of the possibility of increased risk of developing neurologic serious adverse event …

To implement the appropriate strategies for scale-up interventions to eliminate
onchocerciasis without severe adverse events, clinical and biological factors associated with …